We are pleased to share that Blue Wave Therapeutics has been awarded funding from Innosuisse to support an Innovation Project with implementation partner, with a total project value of approximately CHF 525,000.
We would like to express our sincere gratitude to Innosuisse for its support and for recognizing the innovative potential of this project.
We also warmly acknowledge the trust, collaboration, and scientific excellence of the University of Basel Radiopharmaceutical Chemistry Division, led by Prof. Melpomeni Fani.
Blue Wave Therapeutics’ cutting-edge technology platform, combined with the University of Basel’s world-renowned expertise in radioligand therapy, creates a strong foundation for the development of innovative targeted therapies for hard-to-treat cancers.
This project will enable Blue Wave Therapeutics to advance a second product candidate into its pipeline, following ARAspheres for the treatment of recurrent glioblastoma. The new program focuses on the development of a novel parenterally administered radioligand therapy targeting a defined subtype of renal cancer.
We look forward to working closely with our partners to translate this promising approach into meaningful therapeutic innovation for patients.
